Trials / Completed
CompletedNCT01712438
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human cl rhFVIII |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2018-12-14
- Completion
- 2019-12-20
- First posted
- 2012-10-23
- Last updated
- 2021-01-19
- Results posted
- 2019-10-21
Locations
37 sites across 17 countries: United States, Belarus, Canada, France, Georgia, Germany, India, Italy, Moldova, Morocco, Poland, Portugal, Russia, Slovenia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT01712438. Inclusion in this directory is not an endorsement.